RYTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
RHYTHM PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$88.23+2.06 (+2.39%)
Close on Oct 19, 2026
- Market cap
- $6.05B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2014 to 2025
Gross margin
89.7%
Operating margin
-101.2%
Net margin
-103.6%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +45.8% | +100.2% | – | – | |
| Gross profit | +45.8% | +99.3% | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -59.9% | -244.5% | |
| Return on assets | – | -54.1% | -45.1% | |
| Current ratio | 2.36 | 10.10 | 4.41 | |
| Debt to equity | – | – | 0.78 | |
| Net debt to EBITDA | – | – | -0.28× | |
| Interest coverage | – | – | -9.3× | |
| Inventory turnover | – | – | 0.9× | |
| Capex to revenue | – | – | 0.5% | |
| Diluted shares | 10M | 44M | 65M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Rhythm Pharmaceuticals generated $685.14M from operations and spent $1.72M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$685.14M
Used
$1.72M
Capital expenditure$1.72M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-103.6%
×Asset turnover0.43×
×Equity multiplier5.43×
=Return on equity, FY2025-244.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -103.6% | 0.43× | 5.43× | -244.5% |
| FY2024 | -200.3% | 0.36× | 3.79× | -272.2% |
| FY2023 | -238.5% | 0.22× | 1.65× | -85.1% |
| FY2022 | -766.2% | 0.07× | 1.30× | -66.1% |
| FY2021 | -2207.1% | 0.01× | 1.15× | -30.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
6of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$196.54M
- Cash generatingOperating cash flow above zero-$115.68M
- Return on assets improvedROA up on the prior year-78.3% → -50.1%
- Earnings backed by cashOperating cash flow above net income-$115.68M vs -$196.54M
- Less leverageLong-term debt to assets fell27.6% → 21.0%
- Better liquidityCurrent ratio rose3.24 → 4.41
- No dilutionShare count did not rise61M → 65M
- Gross margin improvedGross margin up on the prior year89.73% → 89.73%
- More efficientAsset turnover rose0.39 → 0.48